BioNTech has successfully crossed the finish line in its bid to acquire fellow German biotech firm CureVac. The transaction is now effectively sealed after the Mainz-based company secured tenders for approximately 81.74% of CureVac’s outstanding shares, comfortably surpassing the minimum acceptance threshold required.
Sector Sentiment Weighed Down by Regulatory Meeting
While BioNTech progresses with integrating its new asset, broader market sentiment in the mRNA sector is facing headwinds. A two-day advisory committee meeting convened by the U.S. Centers for Disease Control and Prevention (CDC), concluding today, has introduced an element of uncertainty. This nervousness stems from recent indications by the U.S. Food and Drug Administration (FDA) pointing toward potentially more stringent authorization pathways for future vaccines. Against this backdrop, BioNTech shares are consolidating within a range around $96 to $97.
Acquisition Details and Next Steps
The definitive numbers confirm the deal’s success: a total of 184,071,410 CureVac shares were tendered during the exchange offer period. For remaining CureVac shareholders, a brief additional acceptance period is now open, running until 12:01 p.m. Eastern Time on December 18, 2025. Following this, BioNTech intends to execute a restructuring that is expected to result in CureVac shares being delisted from national stock exchanges.
Should investors sell immediately? Or is it worth buying BioNTech?
Analyst Confidence Endures
Despite the prevailing regulatory climate, analysts maintain a constructive long-term view. Investment bank Jefferies has reaffirmed its “Buy” rating on BioNTech, accompanied by a price target of $151. This assessment underscores a shifting analytical focus away from pure COVID-19-related revenue and toward the company’s oncology pipeline and the anticipated synergies from the CureVac integration.
The finalized acquisition provides BioNTech with strategic clarity for its future development. However, near-term share price movements remain tethered to sector sentiment, which is currently being influenced by the outcome of the ongoing CDC deliberations.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from December 5 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 5.
BioNTech: Buy or sell? Read more here...
